The Beauty of Aging | songs of wisdom: a beautiful writing full of philosophical references about something we all have in common: aging.
Frontiers in Massive Data Analysis, from the National Research Council, nails some of the challenges of big data. But the challenges for massive data go beyond
via Big data challenges.
Originally posted on at least i have a brain:
So have discovered the Spoon analogy but still refuse to use it… BUT i understand the concept of chronic pain…everyday pain…deciding whether you have the energy to get off the bed…recovery days.
THIS IS a GOOD DIAGRAM representing invisible conditions.
I don’t have any listed but it covers connective tissue disorders, neurological conditions, brain malformations…even depression.
The easiest answer on the ODD day that you are OUT and met in town , to the question “How…
View original 434 more words
Two studies, whose material encompassed the Independent workers health plan data base, analyze the consumption of tranquilizers among various categories of professionals. Lawyers ranked high and pharmacists too.
Lawyers are confronted to conflictual situations by the nature of their work itself and pharmacists are tempted, being surrounded by the product itself; these are the two explanations that I could find for these intriguing results.
Here below are the links to the two studies (I contributed to the second paper).
1-Oxford JournalsMedicine & Health Occupational Medicine Volume 64, Issue 3Pp. 166-171.
Mental health and substance use among self-employed lawyers and pharmacists
S. Leignel1,2,3, J.-P. Schuster1,2,3, N. Hoertel1,2,3, X. Poulain1,2,3 and F. Limosin1,2,3
2-Presse Med. 2011 Apr;40(4 Pt 1):e173-80. doi: 10.1016/j.lpm.2010.10.026. Epub 2011 Jan 11.
[Psychotropic medication use by French active self-employed workers].
[Article in French]
Ha-Vinh P1, Régnard P, Sauze L.
The French regulator ANSM is sued by a patient for not having withdrawn the Mediator from the market in the same timeline as the other developed countries.
Nevertheless the administrative court states that given that the French regulator ANSM speaks in the name of the French State the responsibility of the State is involved in this case should the causality between the product and the disease be shown.
The judgement of the administrative court (in French):
Propensity score gives the probability of a subject in a population to belong to a group of interest such as a treatment group.
Then comparing subjects with the same propensity scores across treatment and no-treatment groups enables the researcher to infer on the effect of the treatment regarding a given outcome even if he works on merely observational data.
But the researcher must beware of the unobserved differences between the group of interest and the comparison group created using the propensity score.
As always the relevance of the model depends on the nature of the covariates entered in it.
Garrido, M. M., Kelley, A. S., Paris, J., Roza, K., Meier, D. E., Morrison, R. S. and Aldridge, M. D. (2014), Methods for Constructing and Assessing Propensity Scores. Health Services Research. doi: 10.1111/1475-6773.12182
Unlike the case control studies the case base studies are well suited to the cross sectional extractions from the reimbursement data bases that we usually do.
The case base studies use the whole population of the database as a control group , including the subjects who are affected by the disease (ie the cases).
Thus, making no difference whether the subjects have the disease or not , the control group is far more easy to constitute.
Citation: Chui TT-T, Lee W-C (2013) A Regression-Based Method for Estimating Risks and Relative Risks in Case-Base Studies. PLoS ONE 8(12): e83275. doi:10.1371/journal.pone.0083275
One more time CNAMTS boys have crunched the numbers from the reimbursement data bases.
They previously had done this exercise in real life for the mediator and they had found cardiac side effects. This time they investigated a new category of blood thinner the NACOs (Nouveaux Anti Coagulants). Unlike the mediator they have concluded that in the short term (3 months) no evidence of any adverse side effects such as bleeding or thrombosis could be found.
The mediator study:
The NACOS study of the risk associated with the initiation of treatment with the new blood thinner in anticoagulant treatment naive patients (3 months of follow up):
The NACOS study of the risk associated with the change in treatment consisting in replacing Warfarin by the new blood thinner in anticoagulant treatment experienced patients (4 months of follow up):
A week-and-a-half ago, the D.C. Circuit upheld the criminal conviction of the owner of a clinic that bilked Medicaid out of millions of dollars: Wheeler owned
via Massaging Medicaid.